GSK: Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe RSV Disease in Japan
November 23, 2024
November 23, 2024
LONDON, England, Nov. 23 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Nov. 22, 2024:
* * *
- First RSV vaccine approved in Japan to help protect 50-59 year olds at increased risk due to certain underlying health conditions
- RSV infections can exacerbate these underlying health conditions and lead to severe outcomes, such as pneumonia, hospitalisation and death/1
- 35 countries, i . . .
* * *
- First RSV vaccine approved in Japan to help protect 50-59 year olds at increased risk due to certain underlying health conditions
- RSV infections can exacerbate these underlying health conditions and lead to severe outcomes, such as pneumonia, hospitalisation and death/1
- 35 countries, i . . .